There is a report from India that an Indian company will soon introduce a generic version of pemetrexed under the brand name Pemnat. The intellectual property laws are different in India, so the company is expecting a generic to be legal at this point, while pemetrexed is still under patent in the United States. The story quotes a cost of Rs 25,500 per vial, which at current exchange rates works out to $563. This is only one-third the cost of the imported drug.